Sorrento Therapeutics (SRNE) Posts Q3 GAAP Loss of 27c/Share

Sorrento Therapeutics (NASDAQ: SRNE) reported Q3 EPS of ($0.27), which may not compare with the analyst estimate of ($0.32). Revenue for the quarter came in at $1.28 million versus the consensus estimate of $760 thousand.

For earnings history and earnings-related data on Sorrento Therapeutics (SRNE) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance
• John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c